ArticleTropical diseases, travel medicine and vaccines2025
Genetic polymorphism of MSP2 and its implications for Plasmodium falciparum resistance in N'Djamena, Chad.
Article in Tropical diseases, travel medicine and vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Genetic polymorphism of Plasmodium falciparum MSP-2 (3D7/IC) and multiplicity of infection in N'Djamena, Chad.Scientific reports · 2026Article
- Genetic diversity of the IC/3D7 allelic family of the merozoite surface protein 2 (MSP2) of Plasmodium falciparum and multiplicity of infection in four health facilities in the Mbouda Health District, Cameroon.Scientific reports · 2026Article
- Resistance profile of the Plasmodium falciparum dihydropteroate synthase gene in three hospitals in the city of Ndjamena, Chad.Scientific reports · 2026Article
- Genetic Diversity and Allelic Distribution ofJournal of parasitology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalaria control is a major challenge for countries in endemic areas, and Chad is one of them. The objective of this study was to determine the genetic diversity of the merozoite surface protein 2 (MSP-2) of Plasmodium falciparum in four health facilities in N’Djamena in order to better understand the variability of circulating strains and its epidemiological implications for malaria control.
methodsBlood samples were collected from 302 patients for both parasitological and molecular analyses. Positive samples were spotted on Whatman paper for molecular analyses. The parasite DNA was extracted by the chelex-100 method. The MSP2 gene was amplified by nested PCR and the revelation of this gene was done on a 1.3% agarose gel. The diversity parameters were calculated from the fragments and the number of alleles obtained. The data obtained were analyzed using SPSS 23 software. The phylogenetic tree of the Pf population was carried out using R software.
resultsThe prevalence of P. falciparum infection was 40.72% with a higher parasite intensity in women (317.81±109.93). Of the samples analyzed, 101 carried the MSP-2 gene (78.21%) on which 12 different alleles were obtained, thus a genetic diversity of 9.37%. A multiplicity of infections of 1.26 was determined with a percentage of 73.26; 25.74 and 1% respectively for monoclonal, double clonal and triple clonal infections. The phylogenetic tree showed 11 clades in four health structures of N’Djamena with parasites that are more or less genetically related.
conclusionA significantly high genetic diversity thus indicates a high intensity of malaria transmission of P. falciparum. in N’Djamena. The multiplicity of infections and the high allelic diversity obtained allow us to understand that the malaria transmission situation in this area is critical and should guide studies of resistance to other antimalarial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.